When a patient with a severe brain injury stops responding, the bedside test for consciousness is a request: squeeze my hand, look at me, move your foot. A patient who is aware but cannot move fails it, and decisions about rehabilitation and life support can follow from that result.
Axoft, a Cambridge, Massachusetts company that makes ultra-soft brain probes, wants to read consciousness from the brain itself. On 19 November it reported early human data behind that plan, from patients at Mass General Brigham and The Panama Clinic.
“Physicians will look for signs of consciousness by prompting a response, but consciousness and the ability to respond are not the same,” said Paul Le Floch, Axoft’s co-founder and chief executive.
What Axoft reported
The human data come from brief, temporary placements of the probes; Axoft says seven of the patients were having planned surgery. The results were presented at three conferences in October and November and have not yet appeared in a peer-reviewed journal.
At The Panama Clinic, five patients had a probe placed briefly in the cortex, and Axoft classified their anaesthetic state. Of the first four, two were recorded awake and two asleep, and Axoft says those recordings then predicted the state of the fifth patient in real time. It calls this a proof of concept for “zero shot decoding of consciousness”, a term that usually means a read-out for a patient the system was not trained on. Axoft’s Jordy Tasserie presented the work at the Neurocritical Care Society’s annual meeting in Seattle, held from 20 to 23 October.
Seven patients at Mass General Brigham and The Panama Clinic had probes placed during planned surgery to remove a tumour or a haematoma, a collection of blood. Axoft says the recordings were stable, with up to 85% of channels picking up the firing of single neurons by Axoft’s measure. Axoft’s Jessica Grossman presented further findings at the Congress of Neurological Surgeons annual meeting in Washington, DC, held from 31 October to 4 November.
Axoft says a comparison of pig and human recordings at Mass General Brigham showed that the probes move with the brain as it pulses, which keeps the same neurons in view without correcting the data afterwards. Axoft’s Jake Swann and Mass General Brigham’s Angelique Paulk presented it at the Society for Neuroscience annual meeting in Washington, DC, held from 14 to 18 November.
The market Axoft has picked
The best-known implant companies, including Neuralink, Synchron and Paradromics, are building long-term implants, starting with people who have paralysis or ALS. Axoft’s first target is measuring consciousness and predicting recovery in patients with disorders of consciousness. Le Floch told Bloomberg in April that helping those patients communicate would come next.
“Every year in the U.S., traumatic brain injuries lead to 2.9 million emergency room visits, with many patients ending up in an unresponsive state,” Le Floch said. He said Axoft wants to give “a much-needed voice to the almost half (43%) of neuro-ICU patients who are misdiagnosed when it comes to their state of consciousness”. The 2014 paper Axoft cites for that figure puts it differently: it says misdiagnosis among patients in a vegetative or minimally conscious state “may be as high as 43%”.
The clinical need is documented. In a study published in the New England Journal of Medicine in 2024 and co-led by Mass General Brigham, 60 of 241 patients with severe brain injury who did not respond to bedside instructions, or 25%, showed on functional MRI or EEG that they were covertly following spoken instructions, such as to imagine opening and closing a hand. Some were assessed in intensive care days after their injury, others months or years later. Mass General Brigham noted that no professional guidelines set out how this testing should be done, and that most centres cannot provide it. Missing it “can have serious consequences, including premature withdrawal of life support, missed signs of awareness, and lack of access to intensive rehabilitation,” said Yelena Bodien, the study’s lead author.
Axoft says the probes could later be used for epilepsy, movement disorders and other neurological conditions. Axoft said in April that it would use its $55 million Series A, led by C.P. Group Innovation, to expand clinical trials, work toward US regulatory approval and build a manufacturing facility in the Boston area.
Signal: Why it matters
A test that tells doctors whether an unresponsive patient is conscious would be a diagnostic product for a large hospital population, and Axoft is gathering human data through brief, temporary placements of its probes, including during operations patients already needed. That lets it build a clinical record without waiting for a long-term implant trial. Precision Neuroscience built its early human record the same way, with its surface array placed temporarily during surgery.
The evidence so far is narrow. The consciousness work classified anaesthetic state in patients with probes placed briefly, and telling awake from anaesthetised is a different task from detecting awareness in a patient who appears unresponsive. The claim of a real-time read-out rests on one patient.
Not disclosed
How many patients Axoft has recorded from since April, when Le Floch told Bloomberg that Axoft had tested its probes temporarily in 11 patients, four of them in Shanghai, and whether the five Panama Clinic patients and the seven surgical patients overlap. Whether the result in the fifth patient has been repeated. When Axoft will record from unresponsive patients in intensive care. Whether the data will be submitted to a peer-reviewed journal. What a consciousness test would cost and who would pay for it.
Forward Radar: What to watch
The first recordings in intensive-care patients with disorders of consciousness.
Peer-reviewed publication of the Mass General Brigham and Panama Clinic data.
The FDA submission Le Floch told Bloomberg in April that Axoft planned to send in 2027, and progress on its manufacturing facility.
Sources
Primary:
- Axoft via Business Wire: Axoft unveils clinical momentum of its ultra-soft Fleuron brain computer interface probes, 19 November 2026
- Axoft via Business Wire: Axoft secures $55M Series A, 29 April 2026
- Axoft via Business Wire: first four cases of the FINESSE first-in-human study, 22 April 2025
- Bodien et al., Cognitive motor dissociation in disorders of consciousness, New England Journal of Medicine, August 2024
- Weijer et al., Ethics of neuroimaging after serious brain injury, BMC Medical Ethics, 2014
Coverage:
- Bloomberg via The Star: US brain implant company tests with patients in China, 4 May 2026
- Mass General Brigham via EurekAlert: International study detects consciousness in unresponsive patients, 14 August 2024
Cross-reference to prior InsideBCI coverage: